NASDAQ: NH

A Next Generation Personalized Healthcare Company

NantHealth™

Disclaimer

This presentation has been prepared by NantHealth, Inc. (the "Company") and may contain forward-looking statements that are based on the Company's current expectations, and projections and forecasts about future events and trends that the Company believes may affect its business, financial condition, operating results and growth prospects. Forward-looking statements are subject to substantial risks, uncertainties and other factors, including but not limited to (1) the structural change in the market for healthcare in the United States, including uncertainty in the healthcare regulatory framework and regulatory developments in the United States and foreign countries; (2) the evolving treatment paradigm for cancer, including physicians' use of molecular information and targeted oncology therapeutics and the market size for molecular information products; (3) physicians' need for precision medicine products and any perceived advantage of our solutions over those of our competitors, including the ability of our comprehensive platform to help physicians treat their patients' cancers; (4) our ability to generate revenue from sales of products enabled by our molecular and biometric information platforms to physicians in clinical settings; (5) our ability to increase the commercial success of our sequencing and molecular analysis solution; (6) our plans or ability to obtain reimbursement for our sequencing and molecular analysis solution, including expectations as to our ability or the amount of time it will take to achieve successful reimbursement from third-party payors, such as commercial insurance companies and health maintenance organizations, and government insurance programs, such as Medicare and Medicaid; (7) our ability to effectively manage our growth, including the rate and degree of market acceptance of our solutions; and (8) our ability to offer new and innovative products and services, attract new partners and clients, estimate the size of our target market, and maintain and enhance our reputation and brand recognition.

For further information regarding risks and uncertainties associated with our business, please refer to our recent public filings with the Securities and Exchange Commission (the "SEC"), including, but not limited to the "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" sections included in our 10-K for fiscal year 2016.

This presentation is dated as of May 1, 2017, and the Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. No representation or warranty, express or implied, is given as to the completeness or accuracy of the information or opinions contained in this document and neither the Company nor any of its directors, members, officers, employees, agents or advisers accepts any liability for any direct, indirect or consequential loss or damage arising from reliance on such information or opinions. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance.

We own or have rights to trademarks and service marks that we use in connection with the operation of our business. NantHealth, Inc. and our logo as well as other protected brands. Solely for convenience, our trademarks and service marks referred to in this presentation are listed without the (sm) and (TM) symbols, but we will assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. Additionally, we do not intend for our use or display of other companies' trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies. We have indicated with (TM) symbols where these third party trademarks are referred to in this presentation.

Opportunity to Address Transformative Shifts Across the Healthcare Continuum

NantHealth

Transition to Patient Centric, Value-Based Care

✓ $750bn of waste in the US

✓ Increased prevalence of value-based models such as Accountable Care Organizations

✓ Lack of coordination / interoperability amongst silos of care

Paradigm shift to Molecular Precise and Real-time Biometric-Driven Medicine

✓ $250bn potential precision medicine market

✓ Evolution toward comprehensive genomic and proteomic analysis

✓ Increased connectivity of biometric devices

✓ Overwhelming amounts of data and facts to arrive at a patient decision

# A Next Generation, Evidence Based, Personalized Healthcare Company

NantHealth

ⓒNantHealth™
Culmination of a
25-Year vision

2016 - Present

- Commercial coverage of GPS Cancer™ by Independence Blue Cross **Independence**
- Drive awareness, adoption and reimbursement of GPS Cancer™
- Increase sales of CLINICS, NantOS and Nant OS apps to healthcare providers, Payors, self-insured
- Broaden usage of solutions among existing clients
- Develop new features and functionality for CLINICS
- Expand in international markets
- Complement internal growth with strategic acquisitions
- Initial Public Offering

2014-2015

- Raised over $500 million to fund growth
- Key management hires
- CLIA/CAP Certification of GPS Cancer™ lab
- Launch of chronic disease program for self-insured Payor
- Acquisition of Harris Health Services Interoperability SOA platform **HARRIS**
- Acquisition of nation's leading healthcare collaboration network (NaviNet) **NaviNet**
- Continue operational, technical and sales force integration
- Accumulated library of 5 issued U.S. and 24 pending U.S. patent applications

2012-2013

Integration of prior acquisitions

eviti
★ Assisteo
VITALITY™
i | SIRONA
net.orange

2011

Acquired Abraxis Health Assets from Celgene

Celgene

2010

NantHealth Founded
Abraxis Bio exit event – Celgene: $3.6B

2009

Abraxis Health: Launched Plan to Establish a Universal Companion Test for all Cancer Therapy and Develop a Neoepitope Driven Cancer Vaccine

2008

APP exit event – Fresenius: $5.6B

2005

Abraxis Bioscience IPO

2001

American Pharmaceutical Partners (APP) IPO

1991

VivoRx

Growth to over 900 employees and approximately 30 million monthly payor-provider transactions

Integrated System Delivering Solutions Across the Domains

Comprehensive Solutions for Providers, Payors & Employers

GPS Cancer™ + NantHealth Technology Solutions

Genomic   Proteomic   Spectrometry

Unique, Comprehensive Molecular Cancer Signature

- Quantitative proteomics
- Whole genome (DNA) and transcriptome (RNA) sequencing
- Tumor-normal matching
- CLIA-certified, CAP-accredited

Rich Web-Based and Mobile Apps for Knowledge, Delivery, and Payor Domains

NantHealth Applications & Products

Lab Information Mgt System	Eviti Advisor	Value Monitor	Secure Messaging	Medicare Access
GPS Access	Eviti Trial Check	Vitality	Referral Management	Doc Exchange
GPS Cancer Report	Health Heritage	VitalsConX	Authorizations	Claim Status Inquiry
Cancer Genome Browser	Outcomes Analytics	DCX Mobile	Eligibility & Benefits	HBox
Cancer Connect	GPS Lab Order	Provider Portal	All Payor Access	GlowCap GlowPack

Eviti Connect	Care Coordination	Patient Portal Health Notebook	Claims	DCX	Clinical Workstation

NantOS™

Middleware Platform with Rich Connectivity Across Ecosystem

NantHealth Clinical Operating System: NantOS

DaVinci	Eviti	cOS	DCX Vitality	NaviNet Open	Fusion	Mobile
Molecular Testing DNA, RNA, Protein Machine Learning Artificial Intelligence	Cancer Treatment Decision	Clinical Operating System	Wireless Connectivity & Adherence	Multi Payor Provider Portal	Interoperability with Insights	Consumer Mobile Platform

NantHealth Solutions

I. Next Generation Cancer Care Coordination

II. Wellness & Disease

III. Oncology Care Model

Blue-Chip, Global Client Base of Leading Healthcare Institutions

Our Global Scale

Highly unique infrastructure and expertise with global scale

>100,000,000
Covered lives on our Patient, Provider and Payor Platforms

~30,000,000
Payor-provider transactions monthly

>75%
Of U.S. oncology practices have used our decision support platform

10s of Billions
Of vital signs captured annually

>30,000
In hospital medical devices integrated

>70%
Of U.S. physicians' offices are connected to our Payor-provider collaboration solution

>2,000
Hospitals use NantOS app workflow provider portal

10,000+
Clinical trials updated weekly

>10 Million
Lives covered by providers and payors with three years of longitudinal data

>900
Employees with > 80 in a clinical function

GPS Cancer

What is GPS Cancer – Genomic Proteomic Spectrometry

Comprehensive Molecular Profiling Targeted Proteogenomic Test is performed in a CAP-accredited and CLIA-certified

Tumor

FFPE

P **GPS Paradigm**

~200,000 RNA Expressing Proteins

Affected Protein Pathways

S **GPS Proteomics**

Quantitative Proteomics By Mass Spectrometry

Cancer Immuno-Biology

VS

G **GPS Contrastor**

Whole Genome DNA
3 Billion Base Pairs
~20,000 Genes

Normal

Actionable Peptide Target

Therapeutic Agent

Chemo Resistance Biomarker

Chemotherapy

Personalized Immunotherapy

Decision Support For Cancer Drug Therapy

Identifying the cancer immuno-biology and actionable target

GPS Cancer By the Numbers

264

Oncologists
Ordering GPS Cancer

Representing patients
from over

25

Health
Plans

452

GPS
Tests
Ordered in Q4

~322,000 Covered Cancer Lives
Including lives covered by pilot studies

27

Ongoing contract
discussions with
payors

3

International
Resellers

8

Payor Contracts
Executed

1

Pivotal Pilot Study

GPS Cancer Trends By the Numbers

Oncologists Ordering GPS Cancer

- Q3 2016: 181
- Q4 2016: 264

Ongoing Contract Discussions with Payors

- Q3 2016: 18
- Q4 2016: 27

GPS Tests Ordered

- Q3 2016: 524 (Commercial 344, Research 180)
- Q4 2016: 452 (Commercial 326, Research 126)

Commercial ■ Research

Commercial GPS Tests Delivered

- Q3 2016: 154
- Q4 2016: 233

12

NantOS

NantOS – Foundation of the Platform


Cloud-based, "middleware" platform

1. *Gathers data from silo-ed systems*

2. *Extracts, transforms, aggregates and contextualizes data*

3. *Shares and integrates data with analytics solutions*

4. *Delivers information on a near real-time basis*

Lab Data Pharmacy Data

Patient Accounting & Financial Systems / Operational Systems

Accessible on Mobile Devices

Electronic Medical Record Patient Health Record

Personal Smart Wearable Sensors Monitoring Medical Devices

Genomic Data Imaging Data

✓ Clinical, financial, molecular profile, and biometric data model

✓ 300+ infrastructure and healthcare specific services that leverage traditional, next-generation and real-time data sources

✓ Accessible APIs that enable distributed application development environments

NantOS Apps – Provider Solutions

NantOS Apps – Eviti Oncology Decision-Support Platform

NantOS Eviti Apps

Eviti Advisor

Oncologists
Decision Support

Eviti Connect

Practice Staff   **Payors/Health Plans**
Pre-Authorization

Eviti Advisor
(Enterprise Edition)

Cancer Centers
Quality Management

Eviti Digital Clinical Libraries (Clinical Knowledge-bases)

• Nearly All Cancers and Cancer Subtypes • 2,500+ Evidence-Based Treatments Level of Evidence
• Outcomes • Costs •Toxicities • >10,000 Clinical Trials

Eviti Resources

Clinical Content Experts, Medical Advisory Board, Clinical Librarians, Oncologists, Actuaries, Oncology Certified Nurses

Journals
Scientific Literature
Clinical Trials

Medical Societies
- ASCO
- ASH
- ASTRO
- ACR

Consensus Groups
- NCCN
- Compendium

Government Agencies
- NCI
- FDA

NantOS Apps – Provider Solutions

Leveraging the NantOS integration platform, this solution helps health systems deliver **collaborative, data-driven care** and enhance care quality, lower cost, and improve population health management

Key Applications

This solution brings together multiple data sources to enable real-time, actionable knowledge for providers. It offers:

- **Patient Portal**: Engage patients in their own care and well-being, and communicate with patients easily and securely

- **Provider Portal:** Equip providers with unified access a 360° view of the patient across disparate locations and episodes of care, increasing provider efficiency and enabling informed care decisions

- **Care Coordination:** Enable seamless collaboration across care settings, including support for post-discharge care coordination, urgent care triage, wellness programs, and transition of care planning

Patient Portal   Provider Portal   Care Coordination   Referral Management   Secure Messaging

NantOS Apps – Device Connectivity

A comprehensive set of software applications and devices that enable capture of patient data both in- and out-of-hospital, providing easy, accurate, and complete documentation

Key Features

- **Simple, automated vital signs collection inside the hospital:**
  - Capture data from 30,000+ medical devices and deliver to the EHR quickly and accurately, reducing time and errors associated with manually data entry
  - Intuitive, tablet-based rounding solution that automates the entire vitals collection workflow, making rounding faster and easier
- **Medication adherence and tracking of biometrics outside the hospital:**
  - Improve medication adherence with patient reminders and caregiver alerts for missed doses
  - Track biometrics such as weight, blood pressure and daily activity using wireless personal health devices to inform the care team of patient status

Raise Productivity

VX VitalsConX™   VT Vitality™

Improve Health

| DeviceConX | VitalsConX | Vitality |

NantOS Apps – By the Numbers

NantOS	**>30 Million** Covered Lives Provider & Patient Engagement Clients	**~74,000** Licensed Users (Provider & Clinician Accounts)	**~230,000** Patient Users (Patient Portal Accounts)
Device connectivity	**30,000** Medical Devices Integrated	**350** Hospitals Using the device connectivity platform	**>25,000** DeviceConX Licenses Sold
	10's of Billions of Vital Signs Annually		**Class I Regulated Medical Device**
Eviti	Personalized evidence-based medical library **>2,500 regimens**	Used at least once by **>4,700** oncology practices, representing greater than 75% of all oncology practices in U.S	Deployed across **19 million+** covered lives

NantOS Apps – Payor Solutions

# NantOS Apps – Payor Solutions

A leading suite of administrative and financial applications that help payors and providers **communicate in real-time, close care gaps, and meet value-based reimbursement objectives**

Key Features

Built on a scalable, cloud-based infrastructure, Payor Solutions combine critical administrative and clinical application and services capabilities including:

- **Rich set of configurable administrative applications**—Eligibility and Benefits, Claims, Referrals, and Authorizations—help to improve health plan efficiency and provider productivity

- **A user-friendly, multi-payor portal** enables the real-time delivery of vital clinical and administrative intelligence to providers so they can quickly and easily communicate across multiple health plans

- **Robust set of value-based applications**—Document Exchange, Advanced Referrals, Coding Considerations— enable health plans and providers to dramatically align and to easily transition to value-based care

- **Eligibility and benefits and Claim Status Inquiry –** information for 750+ commercial, state Medicaid, and Medicare plans

Increase Operational Efficiency

Improve Value-based Outcomes

Eligibility and Benefits   Claim Management   Referrals   Authorizations   Document Exchange   All-Payor Access

Payor Solutions – By the Numbers

36

Sponsored Health Plans

Available on our NaviNet Portal

750+

Health Plans

Available via NaviNet Open All-Payor and Medicare Access Offerings

~30 Million Transactions per Month

50 Million+
Covered Lives

Represented by NaviNet Health Plan Clients

650,000+
Providers

NaviNet is utilized in offices where >70% of the nation's physicians practice

~450,000
Active Users

Transacting on the NaviNet network

Employer Solutions

Precision Hypertension Management Overview

NantHealth Wellness and Hypertension Program

A comprehensive set of software applications, remote monitoring devices and support from a dedicated health coach that help payors and self-insured employers proactively **educate, inspire, and encourage healthy behaviors** within their member populations.

Key Features

NantHealth Wellness and Hypertension program puts members in charge of their health and health goals – while providing the necessary support. The program offers:

- **Wireless tracking of biometrics** allows participants to track biometrics and daily activity using wireless personal health devices connected through a smartphone app

- **Wireless tracking of medication adherence** to ensure members are taking hypertension medications as prescribed

- **Personalized health coach** provides support and knowledge to help participants understand biometric readings and recommend a personalized wellness plan, empowering your members to take control of their health and make healthy lifestyle changes.

- **Reporting and analytics data** shared in real-time through the portal enabling direct access and interactive business analytics

Raise Productivity

Improve Health

Manage Cost

A comprehensive wellness program combining technology and behavioral science to improve health and reduce medical costs

Our Global Scale

Highly unique infrastructure and expertise with global scale

>100,000,000
Covered lives on our Patient, Provider and Payor Platforms

~30,000,000
Payor-provider transactions monthly

>75%
Of U.S. oncology practices have used our decision support platform

10s of Billions
Of vital signs captured annually

>30,000
In hospital medical devices integrated

>70%
Of U.S. physicians' offices are connected to our Payor-provider collaboration solution

>2,000
Hospitals use NantOS app workflow provider portal

10,000+
Clinical trials updated weekly

>10 Million
Lives covered by providers and payors with three years of longitudinal data

>900
Employees with > 80 in a clinical function

Financial Summary

4Q16 Income Statement – Prior Year

- 4Q16 revenue of $24.1MM was up $3.7MM over prior year primarily due to $10.6 NaviNet acquired revenue offset by decline in DCX revenue, due to fewer go lives in the quarter compared to a year ago.

- 4Q16 cost of revenue and operating expenses include $5.0MM in stock-based compensation.

- 4Q16 cost of revenue and operating expenses include NaviNet acquisition.

- 4Q16 other expenses include a $29.8MM impairment charge related to the company's investment in NantOmics.

Income Statement

In US '000

	4Q16 {a}	4Q15 {b}	Variance
Revenue			
Software and hardware	$ 1,028	$ 2,420	$ (1,393)
Software-as-a-service	14,874	9,372	5,501
Maintenance	3,383	2,515	868
Sequencing and molecular analysis	482	-	482
Other services	4,315	6,097	(1,782)
Total Revenue	**24,082**	**20,405**	**3,677**
Cost of Revenue	19,820	10,854	8,966
% of Revenue	*82%*	*53%*	*29%*
Gross Margin	4,263	9,551	(5,288)
% of Revenue	*18%*	*47%*	*-29%*
Selling, general and administrative	21,318	16,635	4,684
Research and development	12,766	7,158	5,608
Amort'n of software license and acquisition-related assets	1,814	760	1,054
Total Operating Expenses	35,898	24,553	11,346
Operating Loss	(31,636)	(15,002)	(16,634)
Add: Interest and other income (expense)	(32,773)	(2,448)	(30,325)
Less: Income taxes	(4,458)	403	(4,860)
Net Loss	**$ (59,951)**	**$ (17,852)**	**$ (42,099)**
% of Revenue	*-249%*	*-87%*	*-161%*

{a} 4Q16 results include $5.0MM in stock-based compensation.
{b} 4Q15 results include $0.1MM in stock-based compensation.

FY16 Income Statement – Prior Year

- FY16 revenue of $100.4MM was up $42.1MM over prior year primarily due to $41.0MM in NaviNet acquired revenue and full year of Harris HCS (Fusion) revenue (versus 2 quarters in FY15), offset by decline in DCX revenue.

- FY16 cost of revenue and operating expenses include $54.0MM in stock-based compensation. Prior year's stock-based compensation was only $1.4MM.

- FY16 cost of revenue and operating expenses include NaviNet acquisition and full year of Fusion (versus 2 quarters in FY15).

- FY16 other expenses include a $29.8MM impairment charge related to the company's investment in NantOmics.

- Income tax benefit of $22.8 million related to the release of deferred tax valuation reserves triggered by the IPO and convertible debt offering events in 2016.

Income Statement

In US '000

	FY16 {a}	FY15	Variance
Revenue			
Software and hardware	$ 8,242	$ 14,616	$ (6,375)
Software-as-a-service	58,359	20,733	37,626
Maintenance	14,238	10,452	3,786
Sequencing and molecular analysis	604	75	529
Other services	18,938	12,427	6,511
Total Revenue	**100,381**	**58,304**	**42,077**
Cost of Revenue	72,334	34,809	37,525
% of Revenue	*72%*	*60%*	*12%*
Gross Margin	28,047	23,495	4,552
% of Revenue	*28%*	*40%*	*-12%*
Selling, general and administrative	120,654	69,021	51,633
Research and development	61,637	23,835	37,802
Amort'n of software license and acquisition-related assets	7,257	1,542	5,715
Total Operating Expenses	189,547	94,398	95,149
Operating Loss	(161,500)	(70,903)	(90,597)
Add: Interest and other income (expense)	(45,413)	(703)	(44,710)
Less: Income taxes	(22,811)	405	(23,216)
Net Loss	**$ (184,102)**	**$ (72,011)**	**$ (112,092)**
% of Revenue	*-183%*	*-124%*	*-60%*

{a} FY16 results include $54.0MM in stock-based compensation.
FY16 GPS cost of revenue = $2.0MM.

Balance Sheet Overview

- Cash and cash equivalents of $160.4MM include $84MM from IPO and $103MM from convertible debt capital raises.

- Current ratio in excess of 3x as of 12/31/16

	December 31, 2016	December 31, 2015	$ Variance
Assets			
Current assets			
Cash and cash equivalents	$ 160,353	$ 5,989	$154,364
Restricted cash	-	-	-
Marketable securities	-	1,243	(1,243)
Accounts receivable, net	13,728	11,472	2,256
Inventories	2,217	2,146	71
Deferred implementation costs	3,336	2,224	1,112
Related party receivables, net	899	1,245	(346)
Prepaid expenses and other current assets	5,046	8,707	(3,661)
Total current assets	185,579	33,026	152,553
Property, plant, and equipment, net	29,139	13,899	15,240
Deferred implementation costs, net of current	7,910	1,930	5,980
Deferred income tax assets, net	-	-	-
Goodwill	131,068	56,718	74,350
Intangible assets, net	119,126	54,971	64,155
Investment in related party	207,197	248,191	(40,994)
Related party receivable, net of current	1,971	1,300	671
Other assets	2,317	1,918	399
Total assets	$ 684,307	$ 411,953	$272,354

Balance Sheet Overview (Cont'd)

- Total interest bearing debt equals $191MM as of 12/31/16

- Related party notes issued for $112.7MM and $7.6MM

Balance sheet

	December 31, 2016	December 31, 2015	$ Variance
Liabilities and Stockholders' / Members' Equity			
Current liabilities			
Accounts payable	$ 6,720	$ 6,447	$ 273
Accrued and other current liabilities	25,231	15,967	9,264
Deferred revenue	17,216	10,656	6,560
Related party payables, net	8,082	10,166	(2,084)
Other current liabilities	-	-	-
Total current liabilities	57,249	43,236	14,013
Deferred revenue, net of current	17,238	17,312	(74)
Related party liabilities	5,612	-	5,612
Related party promissory note	112,666	-	112,666
Related party convertible note, net	7,564	-	7,564
Convertible notes, net	70,810	-	70,810
Deferred income taxes, net	754	-	754
Other liabilities	820	358	1,178
Total liabilities	272,713	60,906	212,523
Redeemable Series F units	-	166,042	(166,042)
Stockholders' / members' equity			
Total stockholders' / members' equity	411,594	185,005	226,589
	$ 684,307	$ 411,953	$272,354